Amphotericin B lipid complex (ABLC): New formulation of a new classic antifungal

N. Madrenys I Brunet, J. M. Torres-Rodríguez

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)


Amphotericin B lipid complex (ABLC) is a new galenic form of amphotericin B at a concentration of 5 mg/ml in a lipid suspension. This formulation is distributed quickly in the reticuloendothelial system. However, it does not accumulate in the kidneys and the blood concentration is less than with conventional amphotericin B. It is active against Candida spp, Cryptococcus neoformans, Aspergillus spp., Fusarium spp., Pseudallescheira boydii, Penicillium marneffei, Histoplasma capsulatum, Paracoccidioides brasiliensis, Coccidiodies immitis, Blastomyces dermatitidis, among others, it also been seen to be active against Leishmania braziliensis. No nephrotoxicity has been observed in the clinical studies performed an antifungal efficacy is similar to that of conventcinal amphotericin B. ABLC is indicated particulary in the treatment of severe fungal infections (candidiasis, aspergillosis, fusariosis, mucormycosis) that do not respond to other antifungals, cases showing nephrotoxicity to amphotericin deoxycholate, requiring high doses of amphotericin B or long treatment periods due to a more aggressive mycosis.
Original languageEnglish
JournalRevista Iberoamericana de Micologia
Issue numberSUPPL. 2
Publication statusPublished - 1 Nov 1996


  • Amphotericin B
  • Lipid complex
  • Mycosis
  • Pharmacokinetic


Dive into the research topics of 'Amphotericin B lipid complex (ABLC): New formulation of a new classic antifungal'. Together they form a unique fingerprint.

Cite this